Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK-1119711A
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK-1119711A is an investigational **AS03-adjuvanted, inactivated split-virion monovalent H5N1 pandemic influenza vaccine** developed by GSK. It was evaluated in a randomized, open-label Phase 2 study of alternative prime-boost vaccination schedules in healthy adults. The vaccine is intended to induce hemagglutinin-specific immune responses against influenza A H5N1 viruses and to support prevention of disease during a potential influenza pandemic.
- Other names
- GSK1119711AGSK-1119711AGSK 1119711A
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on GSK-1119711A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK-1119711A.